UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.15
−2.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 675.0K | 951.0K |
| Cost of Revenue | 211.0K | 572.0K | — | — | — |
| Gross Profit | (211.0K) | (572.0K) | — | 675.0K | 951.0K |
| Operating Expenses | |||||
| R&D Expense | 9.6M | 9.1M | 20.0M | 12.9M | 12.4M |
| SG&A Expense | 23.5M | 20.4M | 12.1M | 8.5M | 6.6M |
| General & Admin Expense | 23.5M | 20.4M | 12.1M | 8.5M | 6.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (211.0K) | (572.0K) | — | — | — |
| Total Operating Expenses | 32.9M | 28.9M | 32.1M | 21.4M | 19.0M |
| Cost and Expenses | 33.1M | 29.5M | 32.1M | 21.4M | 19.0M |
| Operating Income (EBIT) | (33.1M) | (29.5M) | (32.1M) | (20.8M) | (18.1M) |
| Non-Operating | |||||
| Interest Income | 1.5M | 1.0M | 1.3M | 615.0K | — |
| Interest Expense | 42.0K | 71.0K | 71.0K | 82.0K | 6.0K |
| Net Interest Income | 1.4M | 941.0K | 1.2M | 533.0K | (6.0K) |
| Other Non-Op Income/Expense | (2.1M) | 3.0M | (4.6M) | (9.8M) | (6.0K) |
| Non-Operating Income (excl Interest) | 2.0M | (3.0M) | 4.5M | 9.7M | — |
| EBT (Pre-Tax Income) | (35.2M) | (26.6M) | (36.7M) | (30.5M) | (18.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (35.2M) | (26.6M) | (36.7M) | (30.5M) | (18.1M) |
| Earnings from Cont. Ops | (35.2M) | (26.6M) | (36.7M) | (30.5M) | (18.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (35.2M) | (26.6M) | (37.8M) | (31.4M) | (18.1M) |
| Per Share | |||||
| Basic EPS | ($1.67) | ($1.67) | ($5.65) | ($12.80) | ($11.99) |
| Diluted EPS | ($1.67) | ($1.67) | ($5.65) | ($12.80) | ($11.99) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.28 | $0.63 |
| Shares | |||||
| Basic Shares Outstanding | 26.9M | 15.9M | 6.7M | 2.5M | 1.5M |
| Diluted Shares Outstanding | 26.9M | 15.9M | 6.7M | 2.5M | 1.5M |
| Profitability Metrics | |||||
| EBITDA | (34.5M) | (25.9M) | (36.2M) | (30.2M) | (17.9M) |
| D&A | 661.0K | 572.0K | 428.0K | 284.0K | 161.0K |
| EBIT | (35.2M) | (26.5M) | (36.7M) | (30.5M) | (18.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026